For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State ...

Third-Quarter 2023 WST Q3 2023 Earnings 1 Third Quarter Overall Net Sales $747.4M | 8.8% Diluted Earnings Per Share: $2.14 Adjusted Diluted Earnings Per Share: $2.16 "We had a solid quarter of organic net sales growth, driven by our Proprietary Products' high-value product (HVP) and strong Contract Manufacturing components. We are observing a slowdown in restocking trends by large Pharma and Generic customers, which is reflected in our revised guidance. As we look to the fourth-quarter 2023, we anticipate d ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET Company Participants Quintin Lai - Vice President of Investor Relations Eric Green - President & Chief Executive Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Larry Solow - CJS Securities Jacob Johnson - Stephens John Sourbeer - UBS Matt Larew - William Blair David Windley - Jefferies Justin Bowers - Deutsche Bank Derik De Bruin - Bank of America Operator Good day, and than ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Quintin Lai - Vice President of Investor Relations Eric Green - President & Chief Executive Officer Bernard Birkett - Senior Vice President and Chief Financial & Operations Officer Conference Call Participants Larry Solow - CJS Jacob Johnson - Stephens Paul Knight - KeyBanc Derik De Bruin - Bank of America Matthew Larew - William Blair David Windley - Jefferies John Sourbeer - UBS Jus ...

Second-Quarter 2023 WST Q2 2023 Earnings 1 | --- | --- | |-------------------------------------------------------------------------------|-------| | Second Quarter Overall Net Sales $753.8M \| 2.3% | | | | | | Diluted Earnings Per Share: $2.06 Adjusted Diluted Earnings Per Share: $2.11 | | "We had a solid first-half of 2023, and with the momentum of our high-value product capacity expansion projects, we are well positioned for an even better second-half of the year. While COVID-19 related sales continued to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or ot ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2023 Results Conference Call April 27, 2023 9:00 AM ET Company Participants Quintin Lai - IR Eric Green - CEO Bernard Birkett - CFO Conference Call Participants Larry Solow - CJS Securities Paul Knight - KeyBanc Capital Markets Matt Larew - William Blair Jacob Johnson - Stephens Derik De Bruin - Bank of America John Sourbeer - UBS Quintin Lai [Call Starts Abruptly] …conference call. We issued our financial results this morning, and the release has been posted ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 530 Herman O. West Drive, Exton, PA 19341-0645 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: 610-594-2900 Securities re ...

| --- | --- | --- | |---------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | West Pharmaceutical Services, Inc. | | | | Eric M. Green | | | | President, CEO and Chair of the Board | | | March 2023 Investor Conferences Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain "forwardlooking statements" as that term is defined in the Private Securities Litigation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or other ...